The Weber Light Letter: Issue No 2
Share
The Weber Light Letter
From studies to practice: The latest in tPBM and laser therapy for clinicians.
Photobiomodulation | Research | Clinical Practice
Subscribe: The Weber Light Letter
The Weber Light Letter: Issue No. 2
PBM and Systemic Recovery, PTSD, and More!
A Note from Robert
In our last issue, I shared how PBM is moving from experimental to essential in neurology and pain care. This month, I’d like to go a step further.
From conversations with colleagues, patients, and in my recent discussion with Dr. Matthias Wojcik (podcasting coming soon!) One theme keeps coming back: light therapy is a shift in how we think about treatment.
Instead of only suppressing symptoms, we are learning how to restore function at the cellular level.
Beyond Symptom Relief: PBM and Systemic Recovery
In our upcoming podcast discussion, we explored how patients with complex, chronic conditions often face a dead end with conventional care. What we’re now seeing with PBM is:
- Immune modulation – balancing overactive and suppressed immune systems
- Neuroplasticity – supporting brain adaptation after trauma or disease
- Energy restoration – improving mitochondrial function where fatigue has been resistant to treatment
Recent studies are reinforcing this systemic perspective:
- A 2025 trial showed tPBM improved working memory in older adults by modulating resting-state brain networks.
- In acute traumatic brain injury, PBM enhanced cerebral microcirculation and drainage, offering neuroprotection in the critical early stages.
📑 PubMed 2025; Crit Care Med 2025
Clinical takeaway: PBM is not a single-target therapy, it’s a systems-level intervention.
Spotlight: PBM and PTSD
A promising new direction is the use of transcranial photobiomodulation (tPBM) in patients with mild traumatic brain injury (mTBI) who also experience post-traumatic stress disorder (PTSD) symptoms.
A 2025 randomized, placebo-controlled trial found that patients receiving real tPBM showed:
- Improved cognitive performance – significant gains in working memory and verbal learning
- Better sleep quality – patients reported reduced sleep disturbances compared to placebo
- Reduction in PTSD-related symptoms – fewer intrusive thoughts, improved emotional regulation, and overall reduction in clinical severity scores
Meanwhile, the placebo group did not experience these improvements.
Clinical takeaway: tPBM is showing measurable benefits in populations where PTSD, sleep disturbance, and cognitive impairment overlap. For clinicians, this opens a new pathway to support patients for whom conventional therapies may not be enough.
The WeberBrain: Nearing Completion
After years of development, the WeberBrain device is almost ready. The first 80 units are already reserved and will begin shipping in the next 1–2 months.
- Designed for transcranial PBM at home
- Backed by protocols developed in clinical practice
- Built to bridge the gap between hospital-based innovation and everyday accessibility
For many patients and clinicians, this represents the first opportunity to apply structured, brain-focused PBM outside of a clinic. If you’d like to reserve your WeberBrain, reach out via DM.
Upcoming Events
🔹 18th International AAMP Conference – Integrative Oncology October 24–26, 2025 | Scottsdale, AZ Focused on breast cancer prevention, hormone impacts, and integrative strategies in oncology.
🔹 A4M 33rd Annual World Congress December 12–14, 2025 | Las Vegas, NV The leading global meeting on longevity, regenerative medicine, and precision health.
Thank you for being part of this growing community of clinicians, researchers, and practitioners. Together, we are building the foundation for a new era of light medicine.
Robert Weber, M.Sc. Founder, Weber Medical Systems President, International Society for Medical Laser Applications
Source & credit: Weber Medical